The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thats exactly why we need to consolidate, if the plan is to list on nasdaq which would in my opinion be a worth while objective given the high valuations of biotech companies in the US and the ability to raise further funds if and when required. We dont know if the HNI are US based and were looking to come on board knowing full well a share consolidation was planed as they will have seen the detailed plans before investing and are confident in Sar team Remember we dont know when the tox results results will be published, could it be before the completion of the share consolidation ?
D.
If the plan is to obtain a nasdaq listing
A minimum sp usd 5-00, at the time of listing. A 50-1 consolidation equals an sp of less than £2-00 at current sp. If this is the plan news will need to at least double the price of the sp
The sp would need to be over £3.80 a share
to achieve a5-00 usd sp. Could Good tox results and share consolidation more than double the sp from current levels. I would expect do so. or why would the BOD do the consolidation . We will have to wait and see if a nasdaq listing is part of the plan for 2022. It would give a strong foundation to raise funds if required for progressing the clinical trails and also as a negotiating position in any potential take over or merger discussions in future
D.
GLA
As part of my past employment many organisations specify in their investment policy statement, with respect to direct investments in shares, a minimum market cap and a minimum Share price of say £1.
I support the board re the proposed share consolidation and look forward to the update that usually accompanies the interim results published in late Feb /early march, and institutional investors jumping on board.
D.
Potnak
I recall mergers where 2 shares in one co may be exchanged for 5 shares in co two , where there are 2 cos to a merger.
In sareums situation , if for exampleif there was no consolidation and the merger was with gsk for example (current share price)
£17-00 ) and gsk for example currently valued Sareum at 20p a share the merger would be 85 shares exchanged for 1 share in gsk.
I can not recall a merger on such multiples.
Would a gsk shareholder be concerned with a share swap of 85 sareum shares for one gsk share. On the other hand if the consolidation of 100 sareum shares to 1 by the BOD, a20p share offer consolidates to £20-00 a share. Therefore in the example above 20 shares in gsk would be exchanged for 17 shares in sareum. Please note this is just an illustration of fgures what could in theory happen upon a share consolidation and merger
GLA
D.
If Sareum was to list shares on the nasdaq
the Board would need to comply with the following
Share holders equity of at least £2m
At least 100k of shares in public vote
A minimum of300 share holders
Total assets of £4m
At least 2 market makers
Public market float minimum of £1m
A mininum bid price of usd 3 bid price of the company stock
Clearly we have no idea what level of consolidation the board are considering
. Hopefully the above will provide some idea the extent of the consolidation if Sareum was to list on nasdaq
Personally the BOD i believe are very experienced and i will support any market consolidation . As part of the consolidation any capital raised may be at a higher price than the newly consolidated SP. Just saying as there are a lot of negative comment on share consolidation with a lower SP, to provide balance. Let this be our year. Personally I think biotech returns could be the new tech in 2022… lets hope so
GLALTH
D:
Lets hope for a positive week next week.
I note British bulls have closed their short recommendation to taking a long position for SAR on friday .
Could be an exciting 6 weeks leading up to Christmas now we have PH on board.
Very noticeable to me that Tim and John were asked to exercise their options(that were due to expire in March 2022) almost as soon as PH were appointed
In my opinion only , PH will be looking to attract institutional investors and it seems their may be active early commercial interest discussions between SAR and possible partners facilitated by PH
D.
Sixthavenue
Tim will also have to consider risk v return .
The risk of failure v the additional return by continuing. He will need to consider the impact of a potential failure on his and his families life style . He cant really sell shares in the market like we as ordinary shareholders can topslice. The market and shareholders would be concerned if Tim and John were to sell part of their holding
It is this logic that i feel that a full sale is likely to be considered in the foreseeable future
GLALTH
D.
Aber
I kind of agree on one hand but on the other , If the BOD are involved in confidential discussions leading to a potentially significant favourable SP movement in the near future, then the BOD would surely be prevented from acquiring shares at this stage in the proceedings, if discussions are close to fruition?
D.
As a lth since the 0.2p days i note a difference with the recent growth in new posters on this BB. There messages often start with a positive comment then leave the reader with a negative conclusion which acts to fester uncertainty . These comments unusually extend to the weekend too. With the new HNVI’s on board, resulting in an excellent bank balance, and the science remains good , and with the market cap growing , and with the end of the holiday season in sight , and with news on the horizon, clearly MM need to acquire shares relatively cheaply. We can expect high volatility in SAR s share price next week in an anticipation of substantial news in the first 2 weeks of September. Just my gut feeling.
D.
T2 i agree totally with your post at 19.49
SAR have negotiated a funding source that raises funds at no cost, with no ‘middle men’ taking their cut. More than that they will as you say , spread the word to wealthy family trusts and business associates who are also HNWI’s. More than the
those middle men who missed out on the
fundraise will have to buy in the open market inorder to build a sizeable holding in SAR. Can only be good for SAR SP
D.
Has any one any views as to how long before we know when the patent has been granted. The average time is around 2.5 years but i would think given that it is, we believe covid related and sar applied almost 16 months ago, one would think their would be pressured being applied to the Patent Office to speed the registration along, in which case the outcome may be known soon IMO
D.